空腹時血糖異常患者における水素水摂取による腸内細菌叢の変容を介した代謝障害の改善：無作為化対照試験
A double-blind, placebo-controlled randomized trial enrolled 73 patients with impaired fasting glucose (IFG), who received either 1000 mL/day of hydrogen-rich water (HRW) or plain water for 8 weeks. HRW produced a significantly greater reduction in fasting blood glucose compared with placebo. Among participants with pre-existing fatty liver, remission was achieved in 62.5% (10/16) of the HRW group versus 31.6% (6/19) in the control group. Fecal 16S RNA sequencing demonstrated that HRW partially corrected gut microbiota dysbiosis. Pearson correlation analysis linking 16S-derived microbial profiles with metabolomics data identified strong associations between altered microbial taxa and nine specific metabolites, suggesting a gut microbiota-mediated mechanism underlying the metabolic improvements observed with HRW.
HRW appears to correct gut microbiota dysbiosis in IFG patients, with altered microbial composition correlating strongly with nine metabolites, suggesting a microbiota-metabolome axis through which H2 exerts its effects on glucose and lipid metabolism.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/37371975